These medicines were studied in people with type 2 diabetes who also had heart disease or were at high risk for heart disease
BPC-157 can complement physical therapy, rehabilitation programs, and other regenerative treatments to accelerate healing and improve outcomes
Clinical trials (SURPASS and SURMOUNT programmes) have shown that dual agonists may offer improved glycaemic control and weight reduction compared to GLP-1 monotherapy
A review of potential options for therapeutic intervention
"We are not saying that semaglutide reverses aging or makes people younger," said the study's first author, Michael Corley, associate professor at UC San Diego School of Medicine and the Stein Institute for Research on Aging, in a press statement
This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide